Source comparison
Tesamorelin + Ipamorelin Blend: Research Application Comparison
Visceral Adipose Reduction 15–18% VAT reduction at 26 weeks (phase III data); direct GHRH receptor-driven lipolysis 5–8% VAT reduction; indirect effect via GH elevation only 18–24% VAT reduction; synergistic lipolysis from sustained GH pulse amplitude + freque
This comparison does not assign a generated winner or score.
- Visceral Adipose Reduction
- 15–18% VAT reduction at 26 weeks (phase III data); direct GHRH receptor-driven lipolysis
- 5–8% VAT reduction; indirect effect via GH elevation only
- 18–24% VAT reduction; synergistic lipolysis from sustained GH pulse amplitude + frequency
- Blend demonstrates additive VAT-specific effect. Tesamorelin's direct adipocyte signaling amplified by Ipamorelin's maintenance of pulsatile release
- IGF-1 Elevation Duration
- Peak IGF-1 at weeks 4–6, plateau by week 10–12 due to somatostatin feedback
- Peak IGF-1 at weeks 3–5, decline by week 8–10 from receptor desensitization
- Sustained IGF-1 elevation through week 12–16; dual-pathway prevents single-mechanism plateau
- Blend extends effective observation window by 4–6 weeks. Critical for long-duration metabolic studies
- Cortisol Impact
- Minimal (GHRH pathway does not stimulate ACTH)
- <5% above baseline (selective GHS-R1a agonism)
- <5% above baseline; no additive cortisol elevation
- Non-selective secretagogues elevate cortisol 40–60%, directly counteracting lipolysis. Blend avoids this entirely
- Dosing Complexity
- Once daily pre-sleep; straightforward
- Twice daily (fasted AM + pre-sleep) for sustained coverage
- Combined once or twice daily depending on protocol; moderate complexity
- Timing flexibility allows customization. Once-daily evening dosing sufficient for most models
- Receptor Downregulation Risk
- Moderate to high after 10–12 weeks of continuous use
- Moderate after 8–10 weeks; faster desensitization than GHRH analogs
- Low to moderate; dual-pathway delays onset of feedback inhibition
- Washout still recommended at 12–16 weeks, but functional window is 30–50% longer than single-peptide protocols
- The comparison clarifies why the blend is preferred for extended metabolic research: neither peptide alone sustains peak efficacy beyond 8–10 weeks, but the combination delays plateau by 4–6 weeks and produces synergistic VAT reduction that exceeds the sum of individual effects.